Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CLEC2 FUSION PROTEIN AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/072550
Kind Code:
A3
Abstract:
Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.

Inventors:
HSIEH SHIE-LIANG (TW)
SUNG PEI-SHAN (TW)
Application Number:
PCT/US2021/052725
Publication Date:
June 09, 2022
Filing Date:
September 29, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ACADEMIA SINICA (CN)
SHIH MING CHE (US)
International Classes:
A61K39/145; A61K38/17; A61K47/68; A61P11/00; C07K14/705; C07K19/00
Domestic Patent References:
WO2012174504A22012-12-20
WO2009037525A12009-03-26
WO2020047107A12020-03-05
Other References:
DATABASE protein ANONYMOUS : "Chain A, Ig gamma-1 chain C region - Protein - NCBI", XP055942414
SUNG, P. ET AL.: "CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections", FRONTIERS IN IMMUNOLOGY, vol. 10, no. 2867, 6 December 2019 (2019-12-06), pages 1 - 9, XP055942415, DOI: 10.3389/fimmu.2019.02867
Attorney, Agent or Firm:
CARR, Nan Z. et al. (US)
Download PDF: